Because high circulating CXCL10 functions as a systemic decoy that redirects anti-tumor immune cells away from the primary site, a complementary therapeutic approach is the systemic neutralization of this chemokine using monoclonal antibodies (mAb) (Figure 3-B). The gene discussed is CXCL10; the disease is neoplasm.